Author

Samarpana Chakraborty

Albert Einstein College of MedicineORCID 0009-0005-1273-7960Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:human· 1

Frequent Co-Authors

Aditi ShastriiD· 3 shared Amit K. VermaiD· 2 shared Kira GritsmaniD· 2 shared Marina Y KonoplevaiD· 2 shared Aaliyah BattleiD· 1 shared Abdullah KhasawnehiD· 1 shared Adrianna Moszyńska· 1 shared Aniela Gołas· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Aditi ShastriORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyLeukemiaPeer-reviewedSep 28, 2026

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells

Shira G. Glushakow-Smith, Imit Kaur, Simone Sidoli…·Kira Gritsman

This study identifies a resistance mechanism in AML leukemic stem cells to PI3K inhibition and shows that combining PI3K and EZH1/2 inhibitors overcomes resistance.

DOI 10.1038/s41375-026-03145-4

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyLeukemiaPeer-reviewedFeb 17, 2026

A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia

Samarpana Chakraborty, Claudia Morganti, Kimberly S. Zaldana…·Aditi Shastri

This paper shows that targeting STAT3 with a degrader can overcome Venetoclax resistance in AML by reducing MCL1 and improving mitochondrial function.

14 citationstop 1%

mouseproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 15, 2026

Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

Urszula Pakulska, Marta Obacz, Jerzy Woźnicki…·Milena M. Mazan

This study shows that romaciclib combined with venetoclax overcomes venetoclax resistance in AML through synergistic apoptosis induction and suppression of resistance pathways.

3 citations

humanproteomics

𝕏 PostBluesky